BioNTech SE Ownership | Who Owns BioNTech SE?
BioNTech SE Ownership Summary
BioNTech SE is owned by 21.52% institutional investors, 62.69% insiders, and 15.79% retail investors. Baillie gifford is the largest institutional shareholder, holding 3.43% of BNTX shares. Franklin All Country World ex US Equity is the top mutual fund, with 8.32% of its assets in BioNTech SE shares.
BNTX Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | BioNTech SE | 21.52% | 62.69% | 15.79% |
Sector | Healthcare Stocks | 279.42% | 10.64% | -190.05% |
Industry | Biotech Stocks | 64.05% | 10.69% | 25.27% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Baillie gifford | 8.22M | 3.43% | $936.74M |
Fmr | 7.70M | 3.21% | $877.58M |
Flossbach von storch | 4.41M | 1.84% | $502.16M |
Primecap management co/ca/ | 4.30M | 1.79% | $489.51M |
Pfizer | 3.66M | 1.53% | $416.87M |
Blackrock | 1.90M | 0.79% | $152.32M |
Blackrock funding, inc. /de | 1.86M | 0.77% | $211.54M |
Temasek (private) | 1.81M | 0.75% | $205.93M |
Capital investors | 1.42M | 0.59% | $161.30M |
Morgan stanley | 1.15M | 0.48% | $92.24M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Bill & melinda gates foundation | 148.67K | 19.99% | $11.95M |
Pfizer | 3.66M | 16.08% | $416.87M |
Crocodile capital partners gmbh | 29.59K | 9.39% | $3.37B |
Krensavage asset management | 132.29K | 4.88% | $10.63M |
Logos global management lp | 300.00K | 4.00% | $34.19M |
Altrinsic global advisors | 627.49K | 3.46% | $71.50M |
Quinn opportunity partners | 356.19K | 2.74% | $40.59M |
Tang capital management | 270.00K | 2.04% | $30.77M |
Flossbach von storch | 4.41M | 2.00% | $502.16M |
Systrade | 10.00K | 1.79% | $1.05M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Pfizer | 3.66M | 16.08% | 3.66M |
Fmr | 7.70M | 0.05% | 1.40M |
Bnp paribas arbitrage, snc | 614.30K | 0.04% | 614.30K |
Dz bank ag deutsche zentral genossenschafts bank, frankfurt am main | 501.90K | 0.06% | 433.39K |
Ubs group | 529.05K | 0.01% | 406.07K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Capital world investors | - | - | -955.98K |
Viking global investors lp | - | - | -879.97K |
Citadel advisors | 66.21K | 0.00% | -412.67K |
Point72 asset management | - | - | -361.99K |
Price t rowe associates inc /md/ | - | - | -313.79K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Pfizer | 3.66M | 16.08% | 3.66M | $416.87M |
Bnp paribas arbitrage, snc | 614.30K | 0.04% | 614.30K | $70.00M |
Logos global management lp | 300.00K | 4.00% | 300.00K | $34.19M |
Susquehanna fundamental investments | 123.66K | 0.20% | 123.66K | $14.09M |
Bank julius baer & co. ltd, zurich | 56.68K | 0.02% | 56.68K | $7.13M |
Sold Out
Holder | Change |
---|---|
Harbor investment advisory | -1.00 |
Halbert hargrove global advisors | -1.00 |
Clear street markets | -1.00 |
Cornerstone planning group | -1.00 |
Signaturefd | -1.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Mar 31, 2025 | 310 | -8.55% | 51,726,357 | 1.91% | 21 | 4.80% | 108 | -28.95% | 105 | 23.53% |
Dec 31, 2024 | 329 | -2.37% | 50,653,251 | 14.51% | 21 | 6.21% | 146 | -7.59% | 84 | -4.55% |
Sep 30, 2024 | 334 | 7.40% | 44,218,941 | 7.90% | 18 | 6.35% | 155 | 31.36% | 88 | -12.00% |
Jun 30, 2024 | 310 | -1.27% | 40,981,505 | 0.12% | 17 | 5.88% | 117 | -18.18% | 100 | 12.36% |
Mar 31, 2024 | 314 | 0.96% | 40,933,865 | 0.99% | 17 | 5.85% | 143 | -11.73% | 89 | 27.14% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Franklin All Country World ex US Equity | 20.00M | 8.32% | 20.00M |
FvS SICAV Multiple Opportunities F | 2.53M | 1.05% | -200.00K |
Vanguard Capital Opportunity Inv | 2.22M | 0.92% | 54.15K |
Harding Loevner International Eq Instl | 1.29M | 0.54% | -561.45K |
FvS Multiple Opportunities II I | 1.12M | 0.47% | -139.23K |
T. Rowe Price US Mid-Cap Growth Equity | 1.02M | 0.43% | 1.02M |
T. Rowe Price Mid-Cap Growth | 1.02M | 0.43% | 375.10K |
PRIMECAP Odyssey Aggressive Growth | 975.66K | 0.41% | -68.70K |
iShares Biotechnology ETF | 923.41K | 0.38% | 7.89K |
NYLI Merger Arbitrage ETF | 893.33K | 0.37% | - |
BNTX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools